Floatz logo

Eprenetapopt

High-grade Serous Ovarian Cancer

Aprea TherapeuticsSmall moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

115 Active assets in the High-grade Serous Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 2/3BB
Letrozole
Memorial Sloan Kettering Cancer Center
Phase 3BB
Olaparib
Institute of Cancer Research, United Kingdom
Phase 3BB

View all 50 →

Same molecule, other indications

Eprenetapopt is also rated in:

therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CCC
Indicative ·
54 / 100
View asset →
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53Dormant
CCC
Indicative ·
51 / 100
View asset →
mantle cell lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →